$14.19
+1.04 (+7.91%)
Open$13.50
Previous Close$13.15
Day High$14.45
Day Low$13.19
52W High$36.58
52W Low$16.46
Volume—
Avg Volume540.1K
Market Cap262.70M
P/E Ratio38.27
EPS$0.80
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+131.9% upside
Current
$14.19
$14.19
Target
$32.91
$32.91
$27.78
$32.91 avg
$47.11
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 35.20M | 36.29M | 36.66M |
| Net Income | 7.89M | 8.09M | 8.22M |
| Profit Margin | 22.4% | 22.3% | 22.4% |
| EBITDA | 9.70M | 9.50M | 9.77M |
| Free Cash Flow | 3.72M | 4.67M | 3.24M |
| Rev Growth | -4.5% | +16.8% | -1.1% |
| Debt/Equity | 0.47 | 0.47 | 0.55 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |